Bristol-Myers Squibb Reports Q3 2026 Revenue Growth Driven by Growth Portfolio
Bristol-Myers Squibb (BMY) reported third-quarter revenue of $13.1 billion, a 7% year-over-year increase fueled by a 12% rise in its growth portfolio. Key drivers included strong performance from Eliquis, which grew 26%, and significant momentum from Breyanzi and Camzyos. Despite these gains, the company faced a 6% decline in Opdivo revenue as patients transitioned to the new subcutaneous Qvantig formulation. The company raised its full-year revenue guidance to a range of $49.75 billion to $50.25 billion. While management is navigating challenges such as inventory drawdowns for Camzyos and upcoming patent expirations for Eliquis in Europe, they remain focused on long-term efficiency through a $2 billion productivity initiative and significant manufacturing investments in Houston and Indiana.
Tickers: $BMY
Topics: EPS pharmaceutical sales product performance revenue growth